Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: Power and promise of molecular pathological epidemiology

Oncogene

Volumn 33, Issue 23, 2014, Pages 2949-2955

  Ogino, S ^a,b,c   Lochhead, P ^d   Giovannucci, E ^a,c   Meyerhardt, J A ^b   Fuchs, C S ^a,b   Chan, A T ^a,e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF ABERDEEN   (United Kingdom)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

molecular pathologic epidemiology; network medicine; systems biology; systems pathology; translational epidemiology; unique tumor principle

Indexed keywords

ACETYLSALICYLIC ACID; B RAF KINASE; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE CATALYTIC SUBUNIT ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; CARCINOGENESIS; COLORECTAL CANCER; CPG ISLAND; DRUG RESPONSE; GENE MUTATION; GENE SEQUENCE; HEREDITARY COLORECTAL CANCER; HUMAN; MEDICAL SUBJECT HEADINGS; MEDLINE; MICROSATELLITE INSTABILITY; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; ASPIRIN; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION; HUMANS; MOLECULAR EPIDEMIOLOGY; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; SIGNAL TRANSDUCTION; TRANSLATIONAL MEDICAL RESEARCH; TUMOR MARKERS, BIOLOGICAL;

EID: 84902189509     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.244     Document Type: Review

References (169)

1. Algra AM, Rothwell PM. Effects of regular aspirin on long-Term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012; 13: 518-527.
2. Flossmann E, Rothwell PM. Effect of aspirin on long-Term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007; 369: 1603-1613. (Pubitemid 46710123)
3. Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S et al. Long-Term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011; 378: 2081-2087.
4. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348: 891-899. (Pubitemid 36297997)
5. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003; 348: 883-890. (Pubitemid 36297996)
6. Benamouzig R, Uzzan B, Deyra J, Martin A, Girard B, Little J et al. Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial. Gut 2012; 61: 255-261.
7. Dube C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code C et al. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 2007; 146: 365-375. (Pubitemid 351650597)
8. Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol 2012; 23: 1403-1415.
9. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP et al. Long-Term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010; 376: 1741-1750.
10. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012; 379: 1591-1601.
11. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009; 302: 649-658.
12. Bastiaannet E, Sampieri K, Dekkers OM, de Craen AJ, van Herk-Sukel MP, Lemmens V et al. Use of aspirin postdiagnosis improves survival for colon cancer patients. Br J Cancer 2012; 106: 1564-1570.
13. Chia WK, Ali R, Toh HC. Aspirin as adjuvant therapy for colorectal cancerreinterpreting paradigms. Nat Rev Clin Oncol 2012; 9: 561-570.
14. McCowan C, Munro AJ, Donnan PT, Steele RJ. Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality. Eur J Cancer 2013; 49: 1049-1057.
15. Zell JA, Ziogas A, Bernstein L, Clarke CA, Deapen D, Largent JA et al. Nonsteroidal anti-inflammatory drugs: effects on mortality after colorectal cancer diagnosis. Cancer 2009; 115: 5662-5671.
16. Coghill AE, Newcomb PA, Campbell PT, Burnett-Hartman AN, Adams SV, Poole EM et al. Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer. Gut 2011; 60: 491-498.
17. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-716. (Pubitemid 28257578)
18. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007; 356: 2131-2142. (Pubitemid 47010839)
19. Markowitz SD. Aspirin and colon cancer-Targeting prevention? N Engl J Med 2007; 356: 2195-2198.
20. Wang D, Xia D, DuBois RN. The crosstalk of PTGS2 and EGF signaling pathways in colorectal cancer. Cancers 2011; 3: 3894-3908.
21. Myung SJ, Rerko RM, Yan M, Platzer P, Guda K, Dotson A et al. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci USA 2006; 103: 12098-12102. (Pubitemid 44215817)
22. Xia D, Wang D, Kim SH, Katoh H, Dubois RN. Prostaglandin E(2) promotes intestinal tumor growth via DNA methylation. Nat Med 2012; 18: 224-226.
23. Varmus H, Harlow E. Science funding: provocative questions in cancer research. Nature 2012; 481: 436-437.
24. Lam TK, Schully SD, Rogers SD, Benkeser R, Reid B, Khoury MJ. Provocative questions in cancer epidemiology in a time of scientific innovation and budgetary constraints. Cancer Epidemiol Biomarkers Prev 2013; 22: 496-500.
25. Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. J Mol Diagn 2008; 10: 13-27. (Pubitemid 351184831)
26. Kamiyama H, Suzuki K, Maeda T, Koizumi K, Miyaki Y, Okada S et al. DNA demethylation in normal colon tissue predicts predisposition to multiple cancers. Oncogene 2012; 31: 5029-5037.
27. Asada K, Ando T, Niwa T, Nanjo S, Watanabe N, Okochi-Takada E et al. FHL1 on chromosome X is a single-hit gastrointestinal tumor-suppressor gene and contributes to the formation of an epigenetic field defect. Oncogene 2013; 32: 2140-2149.
28. Worthley DL, Whitehall VL, Buttenshaw RL, Irahara N, Greco SA, Ramsnes I et al. DNA methylation within the normal colorectal mucosa is associated with pathway-specific predisposition to cancer. Oncogene 2010; 29: 1653-1662.
29. Goel A, Boland CR. Epigenetics of colorectal cancer. Gastroenterology 2012; 143: 1442-1460, e1441.
30. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ et al. The genomic landscapes of human breast and colorectal cancers. Science 2007; 318: 1108-1113. (Pubitemid 350134889)
31. Estecio MR, Gharibyan V, Shen L, Ibrahim AE, Doshi K, He R et al. LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability. PLoS One 2007; 2: e399.
32. Baba Y, Huttenhower C, Nosho K, Tanaka N, Shima K, Hazra A et al. Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors. Mol Cancer 2010; 9: 125.
33. Bass AJ, Lawrence MS, Brace LE, Ramos AH, Drier Y, Cibulskis K et al. Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genet 2011; 43: 964-968.
34. Hinoue T, Weisenberger DJ, Lange CP, Shen H, Byun HM, Van Den Berg D et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res 2012; 22: 271-282.
35. Yang Q, Dong Y, Wu W, Zhu C, Chong H, Lu J et al. Detection and differential diagnosis of colon cancer by a cumulative analysis of promoter methylation. Nat Commun 2012; 3: 1206.
36. The Cancer Genome Atlas Network.. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-337.
37. Beggs AD, Jones A, El-Bahwary M, Abulafi M, Hodgson SV, Tomlinson IP. Whole-genome methylation analysis of benign and malignant colorectal tumours. J Pathol 2013; 229: 697-704.
38. Xu Y, Hu B, Choi AJ, Gopalan B, Lee BH, Kalady MF et al. Unique DNA methylome profiles in CpG island methylator phenotype colon cancers. Genome Res 2012; 22: 283-291.
39. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12: 298-306.
40. Sidler D, Renzulli P, Schnoz C, Berger B, Schneider-Jakob S, Fluck C et al. Colon cancer cells produce immunoregulatory glucocorticoids. Oncogene 2011; 30: 2411-2419.
41. Dahlin AM, Henriksson ML, Van Guelpen B, Stenling R, Oberg A, Rutegard J et al. Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor. Mod Pathol 2011; 24: 671-682.
42. Edin S, Wikberg ML, Dahlin AM, Rutegard J, Oberg A, Oldenborg PA et al. The distribution of macrophages with a m1 or m2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PLoS One 2012; 7: e47045.
43. Ogino S, Galon J, Fuchs CS, Dranoff G. Cancer immunology-Analysis of host and tumor factors for personalized medicine. Nature Rev Clin Oncol 2011; 8: 711-719.
44. Wang D, Dubois RN. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 2010; 29: 781-788.
45. Fernandez AF, Esteller M. Viral epigenomes in human tumorigenesis. Oncogene 2010; 29: 1405-1420.
46. Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA et al. Tumourinfiltrating T-cell subsets, molecular changes in colorectal cancer and prognosis: cohort study and literature review. J Pathol 2010; 222: 350-366.
47. Ogino S, Fuchs CS, Giovannucci E. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn 2012; 12: 621-628.
48. Berger AH, Knudson AG, Pandolfi PP. A continuum model for tumour suppression. Nature 2011; 476: 163-169.
49. Christie M, Jorissen RN, Mouradov D, Sakthianandeswaren A, Li S, Day F et al. Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/beta-catenin signalling thresholds for tumourigenesis. Oncogene 2013; 32: 4675-4682.
50. Imamura Y, Morikawa T, Liao X, Lochhead P, Kuchiba A, Yamauchi M et al. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF-wild-Type colorectal cancers. Clin Cancer Res 2012; 18: 4753-4763.
51. McFarland CD, Korolev KS, Kryukov GV, Sunyaev SR, Mirny LA. Impact of deleterious passenger mutations on cancer progression. Proc Natl Acad Sci USA 2013; 110: 2910-2915.
52. Chen CC, Er TK, Liu YY, Hwang JK, Barrio MJ, Rodrigo M et al. Computational analysis of KRAS mutations: implications for different effects on the KRAS p.G12D and p.G13D mutations. PLoS One 2013; 8: e55793.
53. Lievre A, Blons H, Laurent-Puig P. Oncogenic mutations as predictive factors in colorectal cancer. Oncogene 2010; 29: 3033-3043.
54. Sepulveda AR, Jones D, Ogino S, Samowitz W, Gulley ML, Edwards R et al. CpG methylation analysis-current status of clinical assays and potential applications in molecular diagnostics: a report of the Association for Molecular Pathology. J Mol Diagn 2009; 11: 266-278.
55. Febbo PG, Ladanyi M, Aldape KD, De Marzo AM, Hammond ME, Hayes DF et al. NCCN Task Force report: evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw 2011; 9(Suppl 5): S1-32, quiz S33.
56. Lao VV, Grady WM. Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol 2011; 8: 686-700.
57. Kitkumthorn N, Mutirangura A. Long interspersed nuclear element-1 hypomethylation in cancer: biology and clinical applications. Clin Epigenet 2012; 2: 315-330.
58. Brennan K, Flanagan JM. Is there a link between genome-wide hypomethylation in blood and cancer risk? Cancer Prev Res (Phila) 2012; 5: 1345-1357.
59. Marusyk A, Almendro V, Polyak K. Intra-Tumor heterogeneity: a looking glass for cancer. Nat Rev Cancer 2012; 12: 323-334.
60. Liao X, Morikawa T, Lochhead P, Imamura Y, Kuchiba A, Yamauchi M et al. Prognostic role of PIK3CA mutation in colorectal cancer: Cohort Study and Literature Review. Clin Cancer Res 2012; 18: 2257-2268.
61. Barault L, Veyries N, Jooste V, Lecorre D, Chapusot C, Ferraz JM et al. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 2008; 122: 2255-2259. (Pubitemid 351542328)
62. Rosty C, Young JP, Walsh MD, Clendenning M, Sanderson K, Walters RJ et al. PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival. PLoS One 2013.
63. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753-762.
64. Tol J, Dijkstra JR, Klomp M, Teerenstra S, Dommerholt M, Vink-Borger ME et al. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer 2010; 46: 1997-2009.
65. Gavin P, Colangelo LH, Fumagalli D, Tanaka N, Remillard MY, Yothers G et al. Mutation profiling and microsatellite instability in stage ii and iii colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res 2012; 18: 6531-6541.
66. Sartore-Bianchi A, Moroni M, Veronese S, Carnaghi C, Bajetta E, Luppi G et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007; 25: 3238-3245. (Pubitemid 47325607)
67. Wu S, Gan Y, Wang X, Liu J, Li M, Tang Y. PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-Analysis. J Cancer Res Clin Oncol 2013; 139: 891-900.
68. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554. (Pubitemid 38541907)
69. Kato S, Iida S, Higuchi T, Ishikawa T, Takagi Y, Yasuno M et al. PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Int J Cancer 2007; 121: 1771-1778. (Pubitemid 47417296)
70. Whitehall VL, Rickman C, Bond CE, Ramsnes I, Greco SA, Umapathy A et al. Oncogenic PIK3CA mutations in colorectal cancers and polyps. Int J Cancer 2012; 131: 813-820.
71. Abubaker J, Bavi P, Al-Harbi S, Ibrahim M, Siraj AK, Al-Sanea N et al. Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population. Oncogene 2008; 27: 3539-3545. (Pubitemid 351793794)
72. Benvenuti S, Frattini M, Arena S, Zanon C, Cappelletti V, Coradini D et al. PIK3CA cancer mutations display gender and tissue specificity patterns. Hum Mutat 2008; 29: 284-288. (Pubitemid 351240601)
73. Farina-Sarasqueta A, van Lijnschoten G, Moerland E, Creemers GJ, Lemmens VE, Rutten HJ et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 2010; 21: 2396-2402.
74. Ollikainen M, Gylling A, Puputti M, Nupponen NN, Abdel-Rahman WM, Butzow R et al. Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma. Int J Cancer 2007; 121: 915-920. (Pubitemid 47106226)
75. He Y, Vant Veer LJ, Mikolajewska-Hanclich I, van Velthuysen ML, Zeestraten EC, Nagtegaal ID et al. PIK3CA mutations predict local recurrences in rectal cancer patients. Clin Cancer Res 2009; 15: 6956-6962.
76. Garcia-Solano J, Conesa-Zamora P, Carbonell P, Trujillo-Santos J, Torres-Moreno DD, Pagan-Gomez I et al. Colorectal serrated adenocarcinoma shows a different profile of oncogene mutations, MSI status and DNA repair protein expression compared to conventional and sporadic MSI-H carcinomas. Int J Cancer 2012; 131: 1790-1799.
77. Souglakos J, Philips J, Wang R, Marwah S, Silver M, Tzardi M et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer 2009; 101: 465-472.
78. Miyaki M, Iijima T, Yamaguchi T, Takahashi K, Matsumoto H, Yasutome M et al. Mutations of the PIK3CA gene in hereditary colorectal cancers. Int J Cancer 2007; 121: 1627-1630. (Pubitemid 47328725)
79. Naguib A, Cooke JC, Happerfield L, Kerr L, Gay LJ, Luben RN et al. Alterations in PTEN and PIK3CA in colorectal cancers in the EPIC Norfolk study: associations with clinicopathological and dietary factors. BMC cancer 2011; 11: 123.
80. Iida S, Kato S, Ishiguro M, Matsuyama T, Ishikawa T, Kobayashi H et al. PIK3CA mutation and methylation influences the outcome of colorectal cancer. Oncology letters 2012; 3: 565-570.
81. Hsieh LL, Er TK, Chen CC, Hsieh JS, Chang JG, Liu TC. Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population. Clin Chim Acta 2012; 413: 1605-1611.
82. Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS et al. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One 2011; 6: e22769.
83. Nosho K, Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Zepf D et al. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 2008; 10: 534-541. (Pubitemid 351770297)
84. Garrido-Laguna I, Hong DS, Janku F, Nguyen LM, Falchook GS, Fu S et al. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. PLoS One 2012; 7: e38033.
85. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C et al. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 2005; 7: 413-421. (Pubitemid 41149657)
86. Tian S, Simon I, Moreno V, Roepman P, Tabernero J, Snel M et al. A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. Gut 2013; 62: 540-549.
87. Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, Nishihara R et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 2012; 61: 847-854.
88. Yamauchi M, Lochhead P, Morikawa T, Huttenhower C, Chan AT, Giovannucci E et al. Colorectal cancer: a tale of two sides or a continuum? Gut 2012; 61: 794-797.
89. Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res 2012; 22: 292-298.
90. Castellarin M, Warren RL, Freeman JD, Dreolini L, Krzywinski M, Strauss J et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 2012; 22: 299-306.
91. Tjalsma H, Boleij A, Marchesi JR, Dutilh BE. A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. Nat Rev Microbiol 2012; 10: 575-582.
92. Galon J, Franck P, Marincola FM, Angell HK, Thurin M, Lugli A et al. Cancer classification using the immunoscore: a worldwide task force. J Transl Med 2012; 10: 205.
93. Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nat Rev Genet 2012; 13: 260-270.
94. Baba Y, Nosho K, Shima K, Hayashi M, Meyerhardt JA, Chan AT et al. Phosphorylated AKT expression is associated with PIK3CA mutation, low stage and favorable outcome in 717 colorectal cancers. Cancer 2011; 117: 1399-1408.
95. Kure S, Nosho K, Baba Y, Irahara N, Shima K, Ng K et al. Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer. Cancer Epidemiol Biomarkers Prev 2009; 18: 2765-2772.
96. Velho S, Oliveira C, Ferreira A, Ferreira AC, Suriano G, Schwartz Jr. S et al. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 2005; 41: 1649-1654. (Pubitemid 40981849)
97. Jehan Z, Bavi P, Sultana M, Abubaker J, Bu R, Hussain A et al. Frequent PIK3CA gene amplification and its clinical significance in colorectal cancer. J Pathol 2009; 219: 337-346.
98. Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-Targeted monoclonal antibodies. Cancer Res 2009; 69: 1851-1857.
99. Prenen H, De Schutter J, Jacobs B, De Roock W, Biesmans B, Claes B et al. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 2009; 15: 3184-3188.
100. Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, Byun DS et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 2008; 68: 1953-1961. (Pubitemid 351416582)
101. Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci USA 2008; 105: 2652-2657. (Pubitemid 351520568)
102. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M et al. Aspirin use, tumor PIK3CA mutation status, and colorectal cancer survival. N Engl J Med 2012; 367: 1596-1606.
103. Kaur J, Sanyal SN. PI3-kinase/Wnt association mediates COX-2/PGE(2) pathway to inhibit apoptosis in early stages of colon carcinogenesis: chemoprevention by diclofenac. Tumour Biol 2010; 31: 623-631.
104. Uddin S, Ahmed M, Hussain A, Assad L, Al-Dayel F, Bavi P et al. Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer. Int J Cancer 2010; 126: 382-394.
105. Pasche B. Aspirin-from prevention to targeted therapy. N Engl J Med 2012; 367: 1650-1651.
106. Neugut AI. Aspirin as adjuvant therapy for colorectal cancer: a promising new twist for an old drug. JAMA 2009; 302: 688-689.
107. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J et al. Tumor microenvironment contributes to innate RAF-inhibitor resistance through HGF secretion. Nature 2012; 487: 500-504.
108. Langley RE, Rothwell PM. Biological markers: potential biomarker for aspirin use in colorectal cancer therapy. Nat Rev Clin Oncol 2013; 10: 8-10.
109. Ghosh S, Matsuoka Y, Asai Y, Hsin KY, Kitano H. Software for systems biology: from tools to integrated platforms. Nat Rev Genet 2011; 12: 821-832.
110. Ogino S, Lochhead P, Chan AT, Nishihara R, Cho E, Wolpin BM et al. Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol 2013; 26: 465-484.
111. Ogino S, Stampfer M. Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J Natl Cancer Inst 2010; 102: 365-367.
112. Ogino S, Chan AT, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 2011; 60: 397-411.
113. Boyle T, Fritschi L, Heyworth J, Bull F. Long-Term sedentary work and the risk of subsite-specific colorectal cancer. Am J Epidemiol 2011; 173: 1183-1191.
114. Curtin K, Slattery ML, Samowitz WS. CpG island methylation in colorectal cancer: past, present and future. Patholog Res Int 2011; 2011: 902674.
115. Hughes LA, Simons CC, van den Brandt PA, Goldbohm RA, de Goeij AF, de Bruine AP et al. Body size, physical activity and risk of colorectal cancer with or without the CpG island methylator phenotype (CIMP). PLoS One 2011; 6: e18571.
116. Kelley RK, Wang G, Venook AP. Biomarker use in colorectal cancer therapy. J Natl Compr Canc Netw 2011; 9: 1293-1302.
117. Hughes LA, Khalid-de Bakker CA, Smits KM, van den Brandt PA, Jonkers D, Ahuja N et al. The CpG island methylator phenotype in colorectal cancer: progress and problems. Biochim Biophys Acta 2012; 1825: 77-85.
118. Limburg PJ, Limsui D, Vierkant RA, Tillmans L, Wang AH, Lynch CF et al. Postmenopausal hormone therapy and colorectal cancer risk in relation to somatic KRAS mutation status among older women. Cancer Epidemiol Biomarkers Prev 2012; 21: 681-684.
119. Hughes LA, Williamson EJ, van Engeland M, Jenkins MA, Giles G, Hopper J et al. Body size and risk for colorectal cancers showing BRAF mutation or microsatellite instability: a pooled analysis. Int J Epidemiol 2012; 41: 1060-1072.
120. Ku CS, Cooper DN, Wu M, Roukos DH, Pawitan Y, Soong R et al. Gene discovery in familial cancer syndromes by exome sequencing: prospects for the elucidation of familial colorectal cancer type X. Mod Pathol 2012; 25: 1055-1068.
121. Rex DK, Ahnen DJ, Baron JA, Batts KP, Burke CA, Burt RW et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol 2012; 107: 1315-1329.
122. Koshiol J, Lin SW. Can Tissue-based immune markers be used for studying the natural history of cancer? Ann Epidemiol 2012; 22: 520-530.
123. Gay LJ, Mitrou PN, Keen J, Bowman R, Naguib A, Cooke J et al. Dietary, lifestyle and clinico-pathological factors associated with APC mutations and promoter methylation in colorectal cancers from the EPIC-Norfolk Study. J Pathol 2012; 228: 405-415.
124. Dogan S, Shen R, Ang DC, Johnson ML, DAngelo SP, Paik PK et al. Molecular epidemiology of EGFR and KRAS mutations in 3026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res 2012; 18: 6169-6177.
125. Kuller LH. Invited commentary: the 21st century epidemiologist-A need for different training? Am J Epidemiol 2012; 176: 668-671.
126. Greystoke A, Mullamitha SA. How many diseases is colorectal cancer? Gastroenterol Res Pract 2012; 2012: 564741.
127. Spitz MR, Caporaso NE, Sellers TA. Integrative cancer epidemiology-The next generation. Cancer Discov 2012; 2: 1087-1090.
128. Rosty C, Young JP, Walsh MD, Clendenning M, Walters RJ, Pearson S et al. Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features. Mod Pathol 2013; 26: 825-834.
129. Campbell PT, Patel AV, Newton CC, Jacobs EJ, Gapstur SM. Associations of recreational physical activity and leisure time spent sitting with colorectal cancer survival. J Clin Oncol 2013; 31: 876-885.
130. Weijenberg MP, Hughes LA, Bours MJ, Simons CC, van Engeland M, van den Brandt PA. The mTOR pathway and the role of energy balance throughout life in colorectal cancer etiology and prognosis: unravelling mechanisms through a multidimensional molecular epidemiologic approach. Curr Nutr Rep 2013; 2: 19-26.
131. Buchanan DD, Win AK, Walsh MD, Walters RJ, Clendenning M, Nagler BN et al. Family history of colorectal cancer in BRAF p.V600E mutated colorectal cancer cases. Cancer Epidemiol Biomarkers Prev 2013; 22: 917-926.
132. Burnett-Hartman AN, Passarelli MN, Adams SV, Upton MP, Zhu LC, Potter JD et al. Differences in epidemiologic risk factors for colorectal adenomas and serrated polyps by lesion severity and anatomical site. Am J Epidemiol 2013; 177: 625-637.
133. Lam TK, Spitz M, Schully SD, Khoury MJ. Drivers of translational cancer epidemiology in the 21st century: needs and opportunities. Cancer Epidemiol Biomarkers Prev 2013; 22: 181-188.
134. Burnett-Hartman AN, Newcomb PA, Potter JD, Passarelli MN, Phipps AI, Wurscher MA et al. Genomic aberrations occuring in subsets of serrated colorectal lesions but not conventional adenomas. Cancer Res 2013; 73: 2863-2872.
135. Ogino S, Beck AH, King EE, Sherman ME, Milner DA, Giovannucci E et al. Respond to The 21st century epidemiologist. Am J Epidemiol 2012; 176: 672-674.
136. Begg CB. A strategy for distinguishing optimal cancer subtypes. Int J Cancer 2011; 129: 931-937.
137. Begg CB, Zabor EC. Detecting and exploiting etiologic heterogeneity in epidemiologic studies. Am J Epidemiol 2012; 176: 512-518.
138. Ogino S, Nosho K, Meyerhardt JA, Kirkner GJ, Chan AT, Kawasaki T et al. Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol 2008; 26: 5713-5720.
139. Morikawa T, Kuchiba A, Yamauchi M, Meyerhardt JA, Shima K, Nosho K et al. Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA 2011; 305: 1685-1694.
140. Phipps AI, Shi Q, Newcomb PA, Nelson GD, Sargent DJ, Alberts SR et al. Associations between cigarette smoking status and colon cancer prognosis among participants in north central cancer treatment group phase iii trial n0147. J Clin Oncol 2013; 31: 2016-2023.
141. Vrieling A, Kampman E. The role of body mass index, physical activity, and diet in colorectal cancer recurrence and survival: a review of the literature. Am J Clin Nutr 2010; 92: 471-490.
142. Ballard-Barbash R, Friedenreich CM, Courneya KS, Siddiqi SM, McTiernan A, Alfano CM. Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. J Natl Cancer Inst 2012; 104: 815-840.
143. Waldron L, Ogino S, Hoshida Y, Shima K, McCart Reed AE, Simpson PT et al. Expression profiling of archival tissues for long-Term health studies. Clin Cancer Res 2012; 18: 6136-6146.
144. Colditz GA, Hankinson SE. The Nurses Health Study: lifestyle and health among women. Nat Rev Cancer 2005; 5: 388-396. (Pubitemid 40637830)
145. Colditz GA. Ensuring long-Term sustainability of existing cohorts remains the highest priority to inform cancer prevention and control. Cancer Causes Control 2010; 21: 649-656.
146. Shanmuganathan R, Nazeema Banu B, Amirthalingam L, Muthukumar H, Kaliaperumal R, Shanmugam K. Conventional and nanotechniques for DNA methylation profiling. J Mol Diagn 2013; 15: 17-26.
147. Damania D, Roy HK, Subramanian H, Weinberg DS, Rex DK, Goldberg MJ et al. Nanocytology of rectal colonocytes to assess risk of colon cancer based on field cancerization. Cancer Res 2012; 72: 2720-2727.
148. Dahlin AM, Palmqvist R, Henriksson ML, Jacobsson M, Eklof V, Rutegard J et al. The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. Clin Cancer Res 2010; 16: 1845-1855.
149. Bae JM, Kim JH, Kang GH. Epigenetic alterations in colorectal cancer: the CpG island methylator phenotype. Histol Histopathol 2013; 28: 585-595.
150. Nosho K, Irahara N, Shima K, Kure S, Kirkner GJ, Schernhammer ES et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One 2008; 3: e3698.
151. Teodoridis JM, Hardie C, Brown R. CpG island methylator phenotype (CIMP) in cancer: causes and implications. Cancer Lett 2008; 268: 177-186.
152. Zlobec I, Bihl MP, Schwarb H, Terracciano L, Lugli A. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer 2010; 127: 367-380.
153. Sanchez JA, Krumroy L, Plummer S, Aung P, Merkulova A, Skacel M et al. Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer. Br J Surg 2009; 96: 1196-1204.
154. Zlobec I, Bihl M, Foerster A, Rufle A, Lugli A. Comprehensive analysis of
155. Phipps AI, Buchanan DD, Makar KW, Burnett-Hartman AN, Coghill AE, Passarelli MN et al. BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics. Cancer Epidemiol Biomarkers Prev 2012; 21: 1792-1798.
156. Yamamoto E, Suzuki H, Yamano HO, Maruyama R, Nojima M, Kamimae S et al. Molecular dissection of premalignant colorectal lesions reveals early onset of the CpG island methylator phenotype. Am J Pathol 2012; 181: 1847-1861.
157. Phipps AI, Buchanan DD, Makar KW, Win AK, Baron JA, Lindor NM et al. KRASmutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. Br J Cancer 2013; 108: 1757-1764.
158. Monzon FA, Ogino S, Hammond EH, Halling KC, Bloom KJ, Nikiforova MN. The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch Pathol Lab Med 2009; 133: 1600-1606.
159. Funkhouser WK, Lubin IM, Monzon FA, Zehnbauer BA, Evans JP, Ogino S et al. Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas: A report of the Association for Molecular Pathology. J Mol Diagn 2012; 14: 91-103.
160. Barry ER, Morikawa T, Butler BL, Shrestha K, de la Rosa R, Yan KS et al. Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature 2013; 493: 106-110.
161. Ogino S, King EE, Beck AH, Sherman ME, Milner DA, Giovannucci E. Interdisciplinary education to integrate pathology and epidemiology: towards molecular and population-level health science. Am J Epidemiol 2012; 176: 659-667.
162. Khoury MJ, Lam TK, Ioannidis JP, Hartge P, Spitz MR, Buring JE et al. Transforming epidemiology for 21st century medicine and public health. Cancer Epidemiol Biomarkers Prev 2013; 22: 508-516.
163. Wuchty S, Jones BF, Uzzi B. The increasing dominance of teams in production of knowledge. Science 2007; 316: 1036-1039. (Pubitemid 46804914)
164. Sharp PA, Langer R. Research agenda. Promoting convergence in biomedical science. Science 2011; 333: 527.
165. Eklof V, Wikberg ML, Edin S, Dahlin AM, Jonsson BA, Oberg A et al. The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. Br J Cancer 2013; 108: 2153-2163.
166. Voutsina A, Tzardi M, Kalikaki A, Zafeiriou Z, Papadimitraki E, Papadakis M et al. Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer. Mod Pathol 2013; 26: 302-313.
167. Phipps AI, Makar KW, Newcomb PA. Descriptive profile of PIK3CA-mutated colorectal cancer in postmenopausal women. Int J Colorectal Dis (e-pub ahead of print 1 June 2013; doi:10.1007/s00384-00013-01715-00388).
168. Day FL, Jorissen RN, Lipton L, Mouradov D, Sakthianandeswaren A, Christie M et al. PIK3CA and PTEN gene and exon mutation-specific clinicopathological and molecular associations in colorectal cancer. Clin Cancer Res (e-pub ahead of print 29 May 2013; doi: 10.1158/1078-0432.CCR-1112-3614).
169. Deming DA, Leystra AA, Nettekoven L, Sievers C, Miller D, Middlebrooks M et al. PIK3CA and APC mutations are synergistic in the development of intestinal cancers. Oncogene 2014; 33: 2245-2254.